AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

Stock Information for AzurRx BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.